Dr. Fizazi and colleagues presented their much anticipated results from the LATITUDE trial at the 2017 American Society of Clinical Oncology (ASCO) annual meeting. LATITUDE is a phase III, double-blind, randomized study that tested androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) vs. ADT + placebo in men newly diagnosed with highrisk metastatic hormone-naïve prostate cancer. Historically, ADT has been the standard of care (SOC), however most men with metastases progress to castrate-resistant prostate cancer (CRPC) driven by the reactivation of androgen receptor (AR) signaling. Dr. Fizazi noted that ADT + docetaxel is the new SOC for men with metastatic hormone naïve disease (with high disease burden) based on results from three randomized controlled trials -GETUG-15, CHAARTED and STAMPEDE. Dr. Fizazi said the rationale for combining AA+P to ADT is threefold: (i) the mechanism of resistance to ADT may develop early, (ii) ADT alone does not inhibit androgen synthesis by the adrenal glands or prostate cancer cells, and (iii) AA+P improves overall survival (OS) in metastatic CRPC patients and reduces tumor burden in high-risk, localized prostate cancer. This suggests a role for treatment with drugs inhibiting extragonadal androgen synthesis prior to the development of CRPC.
(Continued on page 4)
The STAMPEDE clinical trial of nearly 2,000 men shows that adding abiraterone acetate (AA) to a standard initial treatment regimen for highrisk, advanced prostate cancer lowers the relative risk of death by 37%. The three-year survival rate was 76% with standard therapy alone vs. 83% with standard therapy plus AA. This is the largest study of AA as first-line therapy for advanced prostate cancer. The study was presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO®). "Abiraterone not only prolonged life, but also lowered the chance of relapse by 70% and reduced the chance of serious bone complications by 50%," said lead study author Nicholas James, BSc, MBBS, PhD, Professor of Clinical Oncology at Queen Elizabeth And, what they found when they looked at the men's testosterone levels when first diagnosed with prostate cancer, they were significantly lower in the men with aggressive prostate cancers. And, there was even a significant increased risk of mortality from prostate cancer with a lower total testosterone at the time of diagnosis. Now, hey wait a second! Moyad is supposed to spend more time on diet and supplements than this stuff - Editor's Note: Us TOO invites certain physicians and others to provide information and commentary for the Hot SHEET to enrich its content to empower the reader. This column contains the opinions and thoughts of its author and are not necessarily those of Us TOO International. low testosterone at the time of diagnosis could be associated with a more aggressive prostate cancer. And, I said "I think so" based on all the men I had followed throughout the years. But what I also said to this man -I will never forget -is if higher weight and waist size is one of the main causes of a low testosterone, then you would think that one of the smartest things men can do after being treated for prostate cancer (especially localized disease) is to maintain a healthy weight or lose weight. It is interesting in this MD Anderson study that men with a higher BMI (body mass index) did, in fact, have significantly lower levels of total testosterone at diagnosis. It also appears, from another study, that men carrying a low testosterone while on active surveillance could have a higher risk for prostate cancer progression and the need for treatment.
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Additional studies also suggest that these men have a lower likelihood of responding to different types of hormone therapy and even have a higher chance of becoming hormone resistant to drug treatment if they have a lower testosterone level. 3, 4 Other studies have suggested that testosterone is not a predictor of tumor aggressiveness but many of these studies looked at testosterone levels a long time before the diagnosis of prostate cancer. Regardless, if increasing body weight increases the risk of low testosterone and low testosterone and/or higher body weight/waist increases the risk of a more aggressive prostate cancer, 5 then why not make lowering weight/waist before or after prostate cancer treatment about as important as anything else you can do for your health?
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Are you following me on this? Does this make sense? Whatever it takes, or whatever the diet, or even a medical weight loss program… losing weight could make the difference between a nasty tumor and a nicer one for some men. "Hey, has anyone in this house seen my reading glasses!? I had AllBran for dinner last night!!! (Moyad circa 2017 Tumor samples were obtained from 65 of the study participants and these were tested for Tp53, RB1, PTEN, AR-N terminus, AR-C terminus, and Ki67. Tumor DNA was also retrieved for sequencing from 27 tumor biopsies and 70 patient plasma samples. Adding carboplatin to cabazitaxel therapy was safe and improved progression-free survival (PFS) and response rates among study participants overall, the researchers confirmed. At a median follow-up of 21.6 months, median PFS in the overall population (n = 160) was 4.6 months (95% CI, 3.5-5.8) with cabazitaxel vs. 7.4 months (95% CI, 5.6-8.3) with cabazitaxel/ carboplatin (P = 0.004). The AVPC-MS was predictive of treatment outcome. Men with AVPC-MS tumors saw a median PFS of 4.5 months on cabazitaxel and eight months with cabazitaxel and carboplatin (P = 0.0036), compared with 6.8 months and 5.4 months, respectively, among men with AVPC-MS-negative tumors. The excellent results prompted the study to be discontinued after the first interim analysis. Adverse events were comparable in the two groups. High blood pressure (hypertension) only rarely required treatment discontinuation, and only two patients discontinued treatment due to non-fatal low blood potassium (hypokalemia). Two men in each arm died of cerebrovascular events, and 10 men treated with ADT+AA+P died of cardiac disorders compared to six men treated with ADT + placebo. In conclusion, the phase III LATITUDE study demonstrated that ADT+AA+P led to a significantly improved OS with a 38% reduction in risk of death, significantly prolonged rPFS (53% reduction), and improvement across all secondary endpoints. The overall safety profile was consistent with the AA+P regimen reported in metastatic CRPC trials. Based on these findings, Dr. Fizazi states, "The addition of AA+P to ADT can potentially be considered a new SOC for patients with high-risk, newly diagnosed hormone-naïve prostate cancer." Background: Being diagnosed with cancer causes major distress, yet the majority of newly diagnosed cancer patients lack psychological support. Internet interventions overcome many barriers for seeking support. We assess efficacy and feasibility of a web-based minimalcontact stress management intervention (STREAM) for newly diagnosed cancer patients.
Methods:
In a prospective, wait list controlled trial, newly diagnosed cancer patients were randomized within 12 weeks of
(Continued on page 7)
Androgen deprivation therapy (ADT) can be safely reduced from 36 months to 18 months in high-risk prostate cancer patients, according to final results of a randomized phase III trial. However, the statistical design of the study may prevent definitive conclusions on the best duration of treatment. Abdenour Nabid, MD, of Centre Hospitalier Régional Universitaire in Sherbrooke, Quebec, presented results (abstract 5008) of the "Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers" (PCS IV) trial at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago. The trial included 630 men randomized to 36 months (310 men) or 18 months (320 men) of ADT (bicalutamide plus goserelin); all men received radiation therapy (RT) and were followed a median of 9.4 years. All men had high-risk disease, and were well matched between the groups, with a median age of 71 years. The median PSA level in the 36-month group was 16.4 ng/ mL, and in the 18-month group it was 15.4 ng/mL; the median Gleason score was 8 in both groups. In the full cohort, 24.1% of men had locally advanced (clinical stage T3-T4 disease), 44.3% had a PSA level above 20 ng/ mL, and 59.7% had a Gleason score above 7. Overall survival (OS) was similar between the two groups. At five years, the 36-month group had an OS rate of 90.9%, and the 18-month group had an OS rate of 86.1%. At 10 years, these rates were 62.4% and 62.0%, respectively. The hazard ratio (HR) for OS was 1.024 (95% CI, 0.813-1.289; nonsignificant P = 0.8411); a multivariate analysis confirmed this, with an HR of 1.01 (95% CI, 0.80-1.27; P = 0.9431). A quality of life analysis favored the 18-month ADT duration. This was clinically significant and covered multiple aspects. Disease-specific survival was also similar. At 10 years, the HR was 0.948 (95% CI, 0.582-1.546; P = 0.830). Biochemical failure at 10 years was more likely in the 18-month group, at 31.0% compared with 24.8%, for an HR in favor of the longer duration of 0.714 (95% CI, 0.532-0.952; significant P = 0.024). Disease-free survival was similar, with an HR of 0.835 (95% CI, 0.683-1.020; P = 0.0768). "In localized high-risk prostate cancer treated with RT and ADT, ADT duration can be safely reduced from 36 to 18 months," Nabid concluded, adding that 18 months could represent a threshold effect of ADT beyond which little extra benefit is derived. "Eighteen months of ADT represents a new standard of care." That conclusion, though, may be somewhat premature. Susan Halabi, PhD, of Duke University Medical Center in Durham, NC, was the discussant for the session, and she pointed out that a nonsignificant test result from a superiority comparison cannot be used to establish similarity between the two treatments. "The optimal duration of ADT for high-risk localized prostate cancer is not known, and remains a clinically important question."
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Reducing ADT to 18 Months May Be Sufficient in High-Risk Prostate Cancer Adding Abiraterone to Standard Treatment (Continued from page 1) also receive radiation therapy in addition to ADT. A novel approach to the clinical trial design meant this comparison recruited men much more quickly than most academic-led trials, and STAM-PEDE will report randomized data from at least 10 comparisons over two decades. At a median follow-up of 40 months, 262 and 184 deaths had occurred in the standard therapy and the ADT plus AA groups, respectively. Threeyear overall survival (OS) rate was 83% in the ADT plus AA group vs. 76% in the standard therapy group. The addition of AA lowered the relative chance of treatment failure by 71% (measured by worsening scans or symptoms, or elevated PSA levels) compared with standard ADT therapy. Effects were consistent across the different subgroups of men enrolled in the trial. Overall, side effects were similar between the two groups. Severe side effects were more common in the ADT plus AA group, occurring in 41% of men compared with 29% of men in the standard therapy group. Main side effects that occurred more frequently with AA were cardiovascular problems such as high blood pressure; there were also more liver problems with AA. There were two treatmentrelated deaths in the ADT plus AA group and one in the standard therapy group. "This study provides strong evidence to support adding AA to standard hormone therapy, primarily for men with metastatic prostate cancer. It adds to a growing body of evidence that establishes AA as a standard of care in this setting," said ASCO expert Sumanta Kumar Pal, MD. This study was funded by grants from Cancer Research UK, the Medical Research Council, and Janssen, with additional contributions to the STAMPEDE protocol from Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis.
The content in this post has not been reviewed by ASCO and does not necessarily reflect the ideas and opinions of ASCO. Presented at the 2017 ASCO Meeting, abstract LBA5003

One RT Dose Enough for Metastatic Spinal Cord Compression
For patients with advanced, metastatic cancer who develop spinal cord compression, one dose of radiotherapy (RT) is as effective as several doses delivered over multiple hospital visits, according to British researchers at the annual meeting of the American Society of Clinical Oncology (ASCO). The results come from a phase three trial (SCORAD III) conducted in 688 patients, which compared a single 8 Gy dose with 20 Gy delivered in five fractions over five days, and showed that the primary endpoint of ambulatory status at eight weeks was similar in both groups. The patients taking part in this study had metastatic cancer of the prostate (44%), lung (18%), breast (11%), and gastrointestinal tract (11%). The majority (73%) was male, and the median age was 70 years. "For patients with a shortened life expectancy, such as the participants in this trial (who had a median overall survival of 13
(Continued on page 6) Younger men with low-risk prostate cancer had outcomes with AS similar to those of the general population of men who choose AS, according to another study reported at AUA. Threefourths of men younger than 60 remained alive without definitive treatment after five years of follow-up, and more than half remained free of definitive treatment at 10 years. After a median followup of 5.1 years, five men developed metastatic disease and none died of prostate cancer during follow-up for as long as 22 years. "Little information exists about the characteristics and outcomes of younger men who choose AS," Salari added. To inform the issue, investigators at MGH and Sunnybrook Health Sciences Center in Toronto retrospectively reviewed the records for all men who began AS from 1995 to 2016. Of almost 2,200 men, 432 were younger than 60 at the start of AS, and these men formed the basis for data analysis. The men had a median age of 55 and a median PSA level of 4.6 ng/dL at diagnosis; 97.7% of the cancers had a Gleason score ≤6, 91.9% had clinical T1 disease, 92.8% had ≤33% positive cores in prostate biopsies, and 77.2% had ≤20% involvement of any single core. After five years of follow-up, 131/432 men (26%) had undergone definitive treatment, the principal reason being disease progression on biopsy (N=88, 67%). An additional 24 men (18%) opted for definitive treatment because of a rising PSA, and other patient-driven factors accounted for intervention in 15 cases (12%). "This corresponds very closely to the reported numbers for AS patients at large -specifically, older men who are on AS," said Salari. Among men who had definitive treatment, 82 (63%) had radical prostatectomy, 16 (12%) had external-beam radiation therapy, 14 (11%) had brachytherapy, and 17 (13%) had high-intensity focused ultrasound. Analysis of 68 pathologic specimens after definitive treatment showed that 60 of the men still have organ-confined disease (pathologic T2). Statistical analysis of factors that influenced the decision to have definitive treatment identified two independent predictors: >20% involvement of any single biopsy core (HR 1.87, 95% CI 1.27-2.76, P=0.0016) and PSA density ≥0.15 (HR 1.98, 95% CI 1.17-3.35, P=0.011). Age, PSA level, Gleason score, clinical stage, and percent positive cores were not predictive. "I find these data very compelling for young men who at
Surveillance for Prostate Cancer Works for Younger Men
(Continued from page 1) noted, and therefore "may still be better for patients with a longer life expectancy, but we need more research to confirm this." Once cancer spreads to the bones, it commonly affects the spine, the experts explained. Metastatic spinal cord compression develops in about 10% of patients with advanced cancer, and tumors pressing on the spine can cause back pain, numbness, and difficulties with walking. In more severe cases, spinal cord compression can lead to incontinence and paralysis, which obviously have "a devastating impact on quality of life," Dr. Jones commented. At enrollment, 66% of patients had ambulatory state one (1) (able to walk normally) or 2 (able to walk with an aid such as a cane or a walker). Results at eight weeks following RT showed that 114/164 (69.5%) patients treated with a single dose and 129/176 (73.3%) treated with several doses had ambulatory status 1 or 2
(Continued on page 8)
One RT Dose is Enough (continued from page 5) least want to delay radical treatment for a period of years, with the acknowledgement that many of them do end up needing treatment at some point," said Stacy Loeb, MD, of NYU-Langone Medical Center in New York City, the moderator of a news conference that included the study. "Nationwide, rates of AS vary widely, from up to 60% to below 20%," Loeb added. The proportion of younger men who choose AS is unclear. A study of men in Sweden, where AS is standard practice for early stage prostate cancer, showed that 88% of men ages 50 to 59 with very lowweeks), a single dose of RT should now become the standard of care," commented lead investigator Peter Hoskin, MD, from the Mount Vernon Cancer Centre in Middlesex, United Kingdom. "For patients, this means fewer hospital visits and more time with family," he added. "This is a case where less is more," agreed Joshua Jones, MD, from the University of Pennsylvania in Philadelphia, who was speaking as an ASCO expert. "These are results from a large phase three study, and are practice-changing," he said. "But there is one caveat: the patients in this study had a short life expectancy," he emphasized. "For patients who are expected to live longer such as metastatic prostate cancer patients, it may still be better to use several doses of RT," he opined. Dr. Hoskin agreed. "Longer RT may be more effective for preventing regrowth of metastases in the spine," he mpMRI data can reliably select patients who would be candidates for targeted biopsy alone. The investigators concluded that, based on their data, systematic biopsies should always be performed in conjunction with targeted biopsy in men with suspected clinically significant PCa at mpMRI. The men had a median PSA level of 7 ng/mL and median prostate volume of 47 cc. Their median number of random cores and index lesions were 12 and 1, respectively. The median index lesion volume was 0.70 cc. 
P1, "LATITUDE: and Adding Abiraterone…"
The management of metastatic prostate cancer continues to evolve and offers patients further improvements in survival. The study by Fizazi et al. compared ADT plus placebo to ADT + abiraterone acetate + prednisone and found the combination significantly improved survival in men with newly diagnosed metastases. A recent report on the STAMPEDE study had similar findings with significantly higher survival in men receiving the combination. These findings are important but they do present some challenges. Previous data have shown a significant improvement in survival when docetaxel was started with ADT for metastatic disease rather than waiting until disease progression. Similarly, we now see that a benefit also occurs when abiraterone is started early. So, how does a patient now proceed and which of these two options is preferable? One might expect worse side effects using the chemotherapy and it is more complicated to deliver. Patients prefer the abiraterone option due to this drug's lesser toxicity; however, there is the cost issue. Finally, patients may now wonder whether an additional study will be done comparing the two options to determine if one does offer a better survival. The Bottom Line: Adding abiraterone acetate and prednisone to ADT in men with newly diagnosed metastatic disease improves survival over ADT alone and should be discussed with each patient faced with this decision. P1, "Surveillance for…" Can younger men with newly diagnosed, low-risk prostate cancer be managed safely with active surveillance or will their longer survival put them at too much risk? That is the focus of a report by Salari, et al. who analyzed 432 men under age 60 followed for a median duration of 5.1 years. Nearly all men had a Gleason score less than 7. By five years, 26% had undergone definitive therapy, mostly because of changes in pathology, and by 10 years it was about 50%. Importantly, only five men developed metastatic disease by five years; however, 40% of the men who did undergo definitive therapy had non-localized disease. Longer follow-up will be needed to determine their long -term risk. The Bottom Line: AS for men under age 60 does not appear to pose a higher risk than for older men but longer followup is still needed before men can be given mature data.
P2, "MRI Accuracy for…"
There is a growing interest in using targeted mpMRI instead of random biopsies to diagnose prostate cancer. Part of the argument is that it reduces the diagnosis of low-risk disease while primarily finding higher-risk disease. However, the study by Stabile and coworkers questions whether that approach is good enough. They reported that higher-risk cancers were missed when only targeted biopsies were done, and whether or not biopsies were positive or negative. For the latter group, 10% had high-risk disease outside the targeted area. One can argue that missing a high-risk cancer in other areas does not matter for those men whose targeted lesion is positive. But missing 10% of high-risk cancers in men with a negative targeted biopsy is a concern. Based on this study, targeted MRI may not be the right approach at this time. The Bottom Line: mpMRI may miss too many high-risk cancers to be able to replace random biopsies. However, scans should have been read by an independent group to determine if the missed cancers were due to incorrect interpretation. More studies are needed to establish the accuracy of this approach. P4, "Signature for Aggressive..." Tailoring chemotherapy in men with prostate cancer is improving as evidenced by the report from Aparacio, et al. They used a molecular test for the presence of aggressive variant prostate cancer in a study comparing cabazitaxel alone or in combination with carboplatin. For those men with the aggressive variant, the combination improved progression-free survival, although no data were reported on the impact for overall survival, which is definitely needed to confirm these observations. Increasingly, tailoring cancer therapy offers a great opportunity for sparing men from treatments that are unlikely to help their condition. The Bottom Line: Genetic testing to identify an aggressive variant of prostate cancer may help identify men that will benefit from a combination of cabazitaxel and carboplatin.
P5, "Reducing ADT…"
A very important paper on the duration of ADT with external radiotherapy (RT) for high-risk prostate cancer was recently presented at ASCO. Nabid, et al. reported on a randomized study comparing 18 to the standard 36 months of ADT and found no significant difference in survival, but a significant improvement in quality of life. Based on this study, doctors should no longer use the longer duration of therapy and the challenge will be how to ensure that doctors are fully aware of these findings when counseling patients about to receive RT. The Bottom Line: Eighteen months of ADT is now sufficient in combination with external radiation for men with high-risk prostate cancer and should replace the previously recommended 36 months duration.
starting anti-cancer treatment to an immediate or delayed (control group) eight-week, web-based intervention. The intervention consisted of eight modules with weekly written feedback by a psychologist ("minimal-contact") based on well-established stress management manuals. The aim of this study was to evaluate efficacy in terms of improvement in quality of life (QoL) using the Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT-F) scale, decrease in distress using the Distress Thermometer (DT), and anxiety/depression using the Hospital Anxiety and Depression Scale (HADS), as compared to patients in the wait-list group. 120 patients were needed to show (80% power, two-sided α (false-positive rate) of 0.05) a clinically meaningful difference of ≥ 9 in the Functional Assessment of Cancer Therapy (FACT) score after the immediate intervention at eight weeks (T2).
Results:
Of 225 patients who applied online, 128 (57%) were randomized. Median age was 52 (range 22-77) years. Most of the patients (108/128, 84%) were female. The majority of patients were treated in the curative setting (117/128, 91%) with chemotherapy for breast cancer (91/128, 71%). Selfreported DT, which served as a stratification factor, was 
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